KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Globus Medical (GMED) EBIT (2016 - 2025)

Globus Medical (GMED) has disclosed EBIT for 15 consecutive years, with $169.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT rose 180.95% year-over-year to $169.3 million, compared with a TTM value of $479.8 million through Dec 2025, up 189.06%, and an annual FY2025 reading of $479.8 million, up 189.06% over the prior year.
  • EBIT was $169.3 million for Q4 2025 at Globus Medical, up from $137.4 million in the prior quarter.
  • Across five years, EBIT topped out at $169.3 million in Q4 2025 and bottomed at $404000.0 in Q3 2023.
  • Average EBIT over 5 years is $58.9 million, with a median of $54.3 million recorded in 2021.
  • The sharpest move saw EBIT plummeted 99.32% in 2023, then skyrocketed 11805.45% in 2024.
  • Year by year, EBIT stood at $18.2 million in 2021, then surged by 196.86% to $54.0 million in 2022, then plummeted by 81.26% to $10.1 million in 2023, then soared by 495.42% to $60.3 million in 2024, then soared by 180.95% to $169.3 million in 2025.
  • Business Quant data shows EBIT for GMED at $169.3 million in Q4 2025, $137.4 million in Q3 2025, and $76.1 million in Q2 2025.